Investor Quick Links
Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.
About Aspira Women’s Health
Our Mission
Aspira Women’s Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women’s Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Most Recent Press Releases
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
Management to Announce Earnings Results and hold a call at 8:30 am ET November 04, 2024 08:00 ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will…
Aspira Women’s Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024
Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline October 25, 2024 08:00 ET AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic…